Osimertinib in poor performance status patients with T790M-positive advanced non-small-cell lung cancer after progression of first- and second-generation EGFR-TKI treatments (NEJ032B)
Description
<jats:title>Abstract</jats:title><jats:sec> <jats:title>Background</jats:title> <jats:p>Osimertinib is effective in patients with T790M mutation-positive advanced non-small-cell lung cancer (NSCLC) resistant to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). However, its effectiveness and safety in patients with poor performance status (PS) are unknown.</jats:p> </jats:sec><jats:sec> <jats:title>Methods</jats:title> <jats:p>Enrolled patients showed disease progression after treatment with gefitinib, erlotinib, or afatinib; T790M mutation; stage IIIB, IV, or recurrent disease; and PS of 2–4. Osimertinib was orally administered at a dose of 80 mg/day. The primary endpoint of this phase II study (registration, jRCTs061180018) was response rate and the secondary endpoints were progression-free survival (PFS), overall survival (OS), disease control rate, and safety.</jats:p> </jats:sec><jats:sec> <jats:title>Results</jats:title> <jats:p>Thirty-three patients were enrolled, of which 69.7% and 24.2% had PS of 2 and 3, respectively. One patient was excluded due to protocol violation; in the remaining 32 patients, the response rate was 53.1%; disease control rate was 75.0%; PFS was 5.1 months; and OS was 10.0 months. The most frequent adverse event of grade 3 or higher severity was lymphopenia (12.1%). Interstitial lung disease (ILD) was observed at all grades and at grades 3–5 in 15.2% (5/33) and 6.1% (2/33) of patients, respectively. Treatment-related death due to ILD occurred in one patient. Patients negative for activating EGFR mutations after osimertinib administration had longer median PFS than those positive for these mutations.</jats:p> </jats:sec><jats:sec> <jats:title>Conclusion</jats:title> <jats:p>Osimertinib was sufficiently effective in EGFR-TKI-resistant, poor PS patients with T790M mutation-positive advanced NSCLC. Plasma EGFR mutation clearance after TKI treatment could predict the response to EGFR-TKIs.</jats:p> </jats:sec>
Journal
-
- International Journal of Clinical Oncology
-
International Journal of Clinical Oncology 27 (1), 112-120, 2021-10-13
Springer Science and Business Media LLC
- Tweet
Details 詳細情報について
-
- CRID
- 1360013168860625280
-
- ISSN
- 14377772
- 13419625
-
- Data Source
-
- Crossref
- KAKEN